Moul JW - Search Results

1

Detection of previously unidentified metastatic disease as a leading cause of screening failure in a phase III trial of zibotentan versus placebo in patients with nonmetastatic, castration resistant prostate cancer.

Yu EY, Miller K, Nelson J, Gleave M, Fizazi K, Moul JW, Nathan FE, Higano CS. Yu EY, et al. Among authors: moul jw. J Urol. 2012 Jul;188(1):103-9. doi: 10.1016/j.juro.2012.03.008. Epub 2012 May 12. J Urol. 2012. PMID: 22583636 Free PMC article. Clinical Trial.

2

Prognostic significance of DNA ploidy in carcinoma of prostate.

Dejter SW Jr, Cunningham RE, Noguchi PD, Jones RV, Moul JW, McLeod DG, Lynch JH. Dejter SW Jr, et al. Among authors: moul jw. Urology. 1989 May;33(5):361-6. doi: 10.1016/0090-4295(89)90026-5. Urology. 1989. PMID: 2711553 Free article.

3

Immunohistologic detection of prostate cancer pelvic lymph node micrometastases: correlation to preoperative serum prostate-specific antigen.

Moul JW, Lewis DJ, Ross AA, Kahn DG, Ho CK, McLeod DG. Moul JW, et al. Urology. 1994 Jan;43(1):68-73. doi: 10.1016/s0090-4295(94)80267-x. Urology. 1994. PMID: 7506855 Review.

4

Alteration of the tumor suppressor gene p53 in a high fraction of hormone refractory prostate cancer.

Heidenberg HB, Sesterhenn IA, Gaddipati JP, Weghorst CM, Buzard GS, Moul JW, Srivastava S. Heidenberg HB, et al. Among authors: moul jw. J Urol. 1995 Aug;154(2 Pt 1):414-21. doi: 10.1097/00005392-199508000-00024. J Urol. 1995. PMID: 7609105 Review.

5

Black race is an adverse prognostic factor for prostate cancer recurrence following radical prostatectomy in an equal access health care setting.

Moul JW, Douglas TH, McCarthy WF, McLeod DG. Moul JW, et al. J Urol. 1996 May;155(5):1667-73. J Urol. 1996. PMID: 8627850 Clinical Trial.

6

Ki-67 expression is a prognostic marker of prostate cancer recurrence after radical prostatectomy.

Bettencourt MC, Bauer JJ, Sesterhenn IA, Mostofi FK, McLeod DG, Moul JW. Bettencourt MC, et al. Among authors: moul jw. J Urol. 1996 Sep;156(3):1064-8. J Urol. 1996. PMID: 8709308

7

Elevated levels of apoptosis regulator proteins p53 and bcl-2 are independent prognostic biomarkers in surgically treated clinically localized prostate cancer.

Bauer JJ, Sesterhenn IA, Mostofi FK, McLeod DG, Srivastava S, Moul JW. Bauer JJ, et al. Among authors: moul jw. J Urol. 1996 Oct;156(4):1511-6. J Urol. 1996. PMID: 8808919

8

The role of the p53 tumor suppressor gene in prostate cancer: a possible biomarker?

Heidenberg HB, Bauer JJ, McLeod DG, Moul JW, Srivastava S. Heidenberg HB, et al. Among authors: moul jw. Urology. 1996 Dec;48(6):971-9. doi: 10.1016/s0090-4295(96)00365-2. Urology. 1996. PMID: 8973691 Review. No abstract available.

9

Suramin keratosis: a unique skin eruption in a patient receiving suramin for metastatic prostate cancer.

Kenner JR, Sperling LC, Waselenko J, Dawson N, Sau P, Moul JW. Kenner JR, et al. Among authors: moul jw. J Urol. 1997 Dec;158(6):2245-6. doi: 10.1016/s0022-5347(01)68218-1. J Urol. 1997. PMID: 9366363 No abstract available.

10

Biostatistical modeling using traditional preoperative and pathological prognostic variables in the selection of men at high risk for disease recurrence after radical prostatectomy for prostate cancer.

Bauer JJ, Connelly RR, Seterhenn IA, Deausen J, Srivastava S, McLeod DG, Moul JW. Bauer JJ, et al. Among authors: moul jw. J Urol. 1998 Mar;159(3):929-33. J Urol. 1998. PMID: 9474185

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

560 results

Search Page

Filters